Inspyr appoints Ronald Shazer SVP and chief medical officer
Dr. Shazer most recently was CMO of Tracon Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted therapeutics for cancer.
He previously was Senior Director, Clinical Lead Oncology at Pfizer, where he led the clinical development of multiple oncology compounds including antibody drug conjugates, dual targeting T-cell engaging antibodies and immuno-oncology small molecules.
Prior to Pfizer, he was Director, Clinical Research Oncology at Bristol-Myers Squibb and served as the study lead on the registration study for elotuzumab (Empliciti), a therapy for multiple myeloma that subsequently received FDA approval.
He also served as Head of Clinical Development at Arena Pharmaceuticals during which time that company filed a new drug application (NDA) for lorcaserin (Belviq).
Dr. Shazer previously held academic positions in the Department of Medicine at the University of California, San Diego, University of California, Los Angeles School of Medicine and Cedars-Sinai Medical Center.
He received his B.A. in Economics from the University of California, San Diego, M.D. from New York Medical College, and MBA from the Anderson School of Management, University of California, Los Angeles. He completed his residency in internal medicine at Cedars-Sinai Medical Center in 2004. ■
LATEST MOVES FROM Texas
- Xplore Technologies names Robert McFarland to board
- Fossil Group appoints Jeffrey Boyer as CFO
- Houston Wire & Cable elects Roy Haley to board
- Texas Instruments elects Brian Crutcher to board
- Integera appoints Joseph W. Dziedzic as permanent CEO
More inside POST